Abstract
Cell-free protein synthesis (CFPS) has emerged as a novel protein expression platform. Especially the incorporation of non-canonical amino acids (ncAAs) has led to the development of numerous flexible methods for efficient and extensive expression of artificial proteins. Approaches were developed to eliminate the endogenous competition for ncAAs and engineer translation factors, which significantly enhanced the incorporation efficiency. Furthermore, in vitro aminoacylation methods can be conveniently combined with cell-free systems, extensively expanding the available ncAAs with novel and unique moieties. In this review, we summarize the recent progresses on the efficient and extensive incorporation of ncAAs by different strategies based on the elimination of competition by endogenous factors, translation factors engineering and extensive incorporation of novel ncAAs coupled with in vitro aminoacylation methods in CFPS. We also aim to offer new ideas to researchers working on ncAA incorporation techniques in CFPS and applications in various emerging fields.
Introduction
Cell-free protein synthesis (CFPS) has emerged as an effective method for the production of recombinant proteins in specialty applications. By eliminating the cell membrane barrier and cell-viability constraint, CFPS offers several benefits over in vivo protein expression (). Firstly, with the open nature of CFPS, almost any molecule can be manipulated precisely in the system for different research purposes, especially molecules whose incorporation is limited by inefficient transport across the cell membrane (Silverman et al., 2019). Secondly, by being able to disregard cell viability, toxic reagents and difficult to express proteins can be employed in CFPS and even some not biocompatible reaction conditions can be applied (). Finally, without reproducible cells, biosafety can be guaranteed because artificial genes cannot pollute the environment through cells.
Basically, there are two main CFPS platforms: the PURE system (i.e., protein synthesis using purified recombinant elements), and the cell extract system. In the PURE system, all components of the transcription and translation apparatus are purified from cells individually and assembled into a well-defined CFPS system. Although all components can be defined at precise concentration, the tedious purification steps make the PURE platform much more expensive than the cell extract system (Shimizu et al., 2001). Many efforts have been made recently to reduce the costs and labor, such as one-pot purification methods and purification from fewer fusion plasmids (Wang H.H. et al., 2012; Shepherd et al., 2017; Villarreal et al., 2018; ). However, partial component control and modularity may be lost in these approaches. The other system relies on non-defined cell extracts. The crude cell extract is separated by lysing cells, so it contains all the native intracellular translation components. Recombinant proteins are synthesized via cell extract based CFPS with the supplementation of additives, such as energy substrates, NTPs, T7 RNA polymerase, amino acids, and salts (; Figure 1). Due to the simple preparation, the cell extract platform is much cheaper and convenient. Additionally, with the help of ancillary translational factors in the cell extract, this platform also has higher protein yields (). Taken together, both CFPS systems are useful platforms for different applications.
FIGURE 1
Incorporating ncAAs into proteins is an emerging biological research area with fundamental science and engineering benefits. In fundamental science, lots of questions are being answered by ncAA techniques, such as labeling proteins by isotopic or fluorescent ncAAs, and immobilization of protein using ncAAs with special side chains (). Post-translational protein modifications (PTM) are difficult to study due to their rapidly shifting levels in the cell. With PTM-mimicking side-chains of ncAAs, high amounts of homologous PTM proteins can be synthesized for investigation (Park et al., 2011; Rogerson et al., 2015; ). In engineering applications, a growing number of artificial protein applications are also emerging, including antibody-drug conjugates (Si et al., 2016), virus-like particle drug conjugates (), active protein polymers (), and screening of artificial enzymes (Ravikumar et al., 2015).
Over 230 ncAAs have been incorporated into proteins by in vivo or in vitro methods (; ). In living cells, an orthogonal amino-acyl tRNA synthetase/tRNA (aaRS/tRNA) pair is essential to precisely incorporate ncAAs into proteins. The orthogonality means that aaRS can only incorporate ncAAs at the specific tRNA and the tRNA can only be recognized by a corresponding aaRS (). Recently, numerous ncAA aaRS/tRNA pairs were developed based on systems from archaea. For instance, tyrosine derivatives can be installed by Methanococcus jannaschii TyrRS/tRNATyr pair variants and lysine derivatives can be installed by variants of the Methanosarcina mazei or Methanosarcina barkeri PylRS/tRNAPyl (). However, due to great advantages over in vivo research, accelerated studies are concentrating on CFPS to incorporate ncAAs. Firstly, the concentration of ncAA and aaRS/tRNA could be conveniently improved for efficient incorporation without limitation by transport across the cell membrane. Secondly, the negative components, which influence efficient ncAA incorporation, can potentially be eliminated potentially in the open CFPS environment. Thirdly, the subsequent reaction can be performed in situ, avoiding tedious purification from cells (). Finally, even toxic ncAAs, which cannot be employed in living cells, could be used in CFPS combined with in vitro aminoacylation methods (; ; ). Therefore, CFPS is a novel platform for ncAA incorporation with great potential.
However, ncAA incorporation in CFPS suffers from endogenous competition (Figure 1). In order to incorporate ncAAs at precise positions, a special codon should be reassigned. Both stop codons and sense codons have been reassigned in various studies (Zimmerman et al., 2014; Schinn et al., 2017; Stech et al., 2017). There is codon competition between ncAA complexes and endogenous biomolecules, which recognize the codon as a canonical amino acid or translation stop signal, resulting in a truncated or wrong protein instead of the ncAA protein (Figure 1). Fortunately, various strategies were developed to overcome competition at different levels, fully utilizing the advantages of CFPS (; ; ). We summarize and discuss these efficiency improvement efforts in this review. In addition to efficient ncAA incorporation, many novel ncAAs can only be used in CFPS using in vitro aminoacylation methods (Ohta et al., 2008; ; ). These novel amino acids greatly expand the scope and flexibility of CFPS ncAA incorporation, which is also gaining increasing attention.
The purpose of this review is to give an overview of the emerging methods for improving the scope and efficiency of ncAA incorporation in CFPS. We focus on strategies to raise efficiency at the competition elimination and translation factors engineering. Moreover, the novel ncAAs and in vitro aminoacylation methods, that can only be used in CFPS and expand the range of available ncAAs, are given special attention. This review provides a reference for researchers to choose suitable ncAA incorporation techniques for CFPS and expand the research to more potential fields.
Strategies for Eliminating Competition
As shown in Figure 1, the competition for codons, that seriously affects the efficiency of ncAA incorporation, always exists in codon reassignment. Competitors are classified into two categories: peptide release factors and endogenous aminoacyl-tRNA, and methods for eliminating competition include genome engineering, protein elimination, tRNA manipulation, and amino acid replacement (Figure 2). Here, we discuss the challenges and opportunities of these current and emerging methods.
FIGURE 2
Genome Engineering
The amber codon (UAG), which is normally a translation termination signal recognized by peptide release factor 1 (RF1), is most commonly reassigned for ncAA incorporation. Deletion of the prfA gene encoding RF1 is a frequent strategy to improve the ncAA incorporation efficiency in vivo and in vitro (). Cell extracts from such strains have shown numerous advantages (Smolskaya et al., 2020). However, RF1 is essential for translation termination of over 300 genes in the genome, and the direct deletion of prfA could seriously affect cell growth before cell extract preparation, even leading to cell death (). To address this problem, several detailed methods have been developed. These efforts and CFPS applications will be discussed in this section (Figure 2A).
The most direct method is the replacement of all amber codons with other stop codons, producing cells that do not need RF1, so that prfA can be knocked out without affecting cell viability. C321. ΔA is such an E. coli strain, whereby all of its 321 amber codons were replaced with ochre codons (UAA) (). Without RF1 competition, ncAAs can be incorporated into proteins at high efficiency. For instance, phosphoserine was efficiently incorporated into human MEK1 kinase using CFPS based on a cell extract of C321.ΔA, in which robust production reached up to milligram quantities (Oza et al., 2015). By contrast, under RF1 competition in intracellular expression, only 25 μg of MEK1 containing phosphoserine was isolated from 1 liter of culture (Park et al., 2011). Recently, glycosylation enzymes were also successfully synthesized using this CFPS platform (). Furthermore, to improve the CFPS protein production capacity, great efforts were made to further improve C321. ΔA. Combined knockout of the genes endA, gor, rne, and mazF was shown to increase the yield of a model protein about fivefold, with up to 40 ncAAs (). Subsequently, a C321. ΔA variant that can express T7 RNA polymerase from the chromosome was created and optimized. CFPS based on a cell extract of this strain yielded up to 70 μg/mL of a model protein with 40 ncAAs, demonstrating a highly productive one-pot CFPS system ().
In addition to full replacement of amber codons, partial replacement has also been demonstrated, in which only the stop codons of some essential genes were replaced. The strains RFzero, B95.ΔA and rEc.E13.ΔA are representatives of this strategy. The RFzero strain did not contain any replaced stop codons in chromosome. Ingeniously, it was introduced the BCA7 plasmid harboring seven essential genes (coaD, hda, hemA, mreC, murF, lolA, and lpxK) with replaced stop codons for compensation. Subsequently, a chromosomal prfA deletion was carried out successfully, with only a minimal decrease of the cell growth rate (, ; Ohtake et al., 2012). Then, CFPS using a cell extract of the RFzero strain was verified to incorporate six ncAAs with high efficiency and productivity (). The strains B60.ΔA and B95.ΔA were developed from E. coli strain BL21(DE3) by by respectively replacing 60 and 90 chromosomal amber codons before prfA deletion. Due to the rapid growth rates of B60.ΔA and B95.ΔA, a CFPS protocol for highly efficient incorporations of ncAAs was also described in detailed (Seki et al., 2018). Before research on CFPS based on C321.ΔA, Jewett et al., developed the RF1 deletion strain rEc.E13.ΔA, which is homologous to C321.ΔA (, ). In conclusion, by bypassing the time, labor and cost needed for full codon replacement, a partial amber codon replacement strategy is a rapid and simple method for constructing the desired strains, even if the growth rate may be decreased to a certain extent. This method has been applied to diverse E. coli strains for various purposes, including MG1655, HST108, and BL21 (DE3).
In addition to the established strains for CFPS, some genome engineering strains also have considerable potential to incorporate ncAAs in CFPS. Wang et al. found that prfA could be deleted unconditionally in E. coli B strain derivatives. Moreover, after reverting the release factor 2 (RF2) A246T mutation back to Ala, prfA could also be knocked out in E. coli K12 strain derivatives, demonstrating that RF1 is non-essential in E. coli (, ; Wang, 2017). Without any stop codon replacement, it is the most rapid and simple method for RF1-free strain construction.
Although genome engineering provides a completely RF1 elimination strategy without residuals, these above methods also inevitably affect the activity and yield of CFPS and consume time and laborious for genetic manipulation. Consequently, additional strategies were developed for CFPS with unique advantages, which may be combined with genome engineering for future improvement.
Protein Elimination
Because the open reaction environment can be controlled directly, the CFPS system is more flexible than in vivo translation systems. Various competition eliminating strategies are only possible in the CFPS system with its special properties. An important strategy is protein elimination from the CFPS system. By manipulating protein levels, essential proteins can remain active to aid cell growth, but can be removed from the CFPS system to remove competition. For example, RF1 can be selectively removed using affinity tags, deactivating additives, or protease degradation (Figure 2B).
Selective removal of RF1 using an affinity tag has already been demonstrated by Otting et al. This approach requires the genetic fusion of a chitin-binding domain sequence to prfA, so that the wild-type RF1 is replaced by a variant with three continuous chitin-binding domains at the C-terminus, which maintained the peptide release activity required for cell growth. After cell extract preparation, the lysate was filtered through a chitin column to selectively remove the tagged RF1, resulting in an improved CFPS system with efficient ncAA incorporation at multiple sites (; ; ).
Similarly, the RF1 protein can also be eliminated by modifying the protein to make it sensitive to certain factors and eliminating it from the CFPS system. For example, a temperature-sensitive variant of RF1 had been engineered in E. coli, and the cell extract with a thermosensitive RF1 demonstrated a 11-fold increase of efficiency in ncAA incorporation following heat treatment (Short et al., 1999). However, longstanding heat shock may result in the loss of basic activity of the CFPS system, while too little heat can leave residual RF1. Recently, another strategy was developed with no need for heat shock. Yin et al. (2017) successfully inserted an outer membrane protease (OmpT) recognition site into the switch loop of RF1. OmpT protease only identifies extracellular target proteins. Thus, the engineered RF1 can maintain the cell growth rate before cell extract preparation, after which it is cleaved by OmpT during cell lysis, which led to an increase of ncAA incorporation in CFPS.
These protein elimination strategies rely on the modification of proteins by genetic engineering. However, certain additives can also deactivate RF1 in the CFPS system. used an anti-RF1 antibody to block RF1 activity in CFPS and improve the ncAA incorporation efficiency. Nonetheless, the antibody requires expression and purification steps, which increased the costs. Consequently, the easily prepared and adaptable RNA aptamers have also been investigated for RF1 inactivation (Szkaradkiewicz et al., 2002; Shafer et al., 2004). For instance, an RNA aptamer that can orthogonally deactivate RF1 in CFPS was selected from a 50 nt random sequence RNA pool, showing the ability to increase the efficiency of ncAA incorporation (Ogawa et al., 2005; Sando et al., 2007).
RF1 could be removed at either genome or protein level. By comparison, deletion of RF1 gene from genome completely get rid of RF1 bioactivity from cell. And RF1-deficient E. coli cells have demonstrated its potential in preparation of RF1-free cell extraction for incorporation of ncAA into protein. However, knockout of gene for RF1 generated side effects, such as slow cell growth. For instance, C321.ΔA has been evolved to improve cell viability by correcting mistakes of genetic manipulation, such as off-target modifications (Wannier et al., 2018). In contrast, RF1 elimination at protein level requires complicated procedures, such as chromatography, degradation or deactivation (; Sando et al., 2007; ; Yin et al., 2017). On the other hand, without stop codon replacements by multiple-sites genome editing, protein elimination strategy can be easily applied to other strains. However, due to the open nature of CFPS, more strategies can be flexibly designed.
Manipulation of tRNAs
When a ncAA is inserted into a protein at a sense codon, the endogenous aminoacyl-tRNA will compete with the ncAA aminoacyl-tRNA in the ribosome during translation, resulting in partially native protein. Directly manipulating tRNAs in the cell is unrealistic, but it is convenient in CFPS without a membrane barrier, freeing a large number of sense codons for ncAA incorporation by tRNA manipulation (Tajima et al., 2018). Considering the one-to-one correspondence between tRNAs and codons, artificial codon tables, and even minimum codon combinations can be achieved by tRNA manipulation in CFPS (; Wang et al., 2020). Recently, several tRNA level methods were developed, including tRNA pool replacement, elimination using antisense oligonucleotides, and tRNA-specific enzymatic degradation (Figure 2C).
The most direct method is the replacement of all tRNAs with a tRNA pool customized according to research purposes. Due to the molecular weight of ∼25,000 with 70–90 nucleotides in tRNAs, straightforward dialysis is not capable of removing tRNA from cell extracts and some small molecular translation enzymes, such as initiation factor 1, can be lost during dialysis (). Nevertheless, several methods for the replacement of endogenous tRNAs have been developed. Recently, a near-complete endogenous tRNA eliminating method was reported in which RNase A was attached to magnetic beads to remove native tRNAs from cell extract (Salehi et al., 2017). Additionally, semisynthetic tRNA complements, which contain the majority of 48 synthetic tRNAs, were shown to be functional in CFPS, extending the ability to customize additive tRNA pools for ncAA incorporation at multiple sense codons ().
Considering the time-consuming steps required for native tRNA removal and custom tRNA synthesis in the tRNA pool replacement strategy, tRNA antisense oligonucleotides have emerged as a powerful tool for tRNA-specific elimination and inactivation in CFPS. removed the tRNA by DNA-hybridization chromatography of tRNA-specific antisense oligonucleotides, displaying a universal method for sense codon reassignment. However, without additional chromatography steps, methylated anti-tRNA oligonucleotides were demonstrated to deactivate multiple selected tRNAs by tRNA–DNA hybridization, which was induced due to heating and annealing with the tRNA mix of CFPS. This approach is more efficient than chromatography for tRNA inactivation ().
In addition to tRNA-specific antisense oligonucleotides, the tRNAArg-specific tRNase, colicin D, was also utilized for specific tRNA elimination. Colicin D specifically cleaves tRNAArg at the anticodon loop, including tRNA, tRNA, tRNA, tRNA, tRNA, and tRNA, which can free six codons for reassignment (Tomita et al., 2000). Kang et al. utilized resin-bound colicin D to cleave all tRNAArg in the cell-free system and supplemented synthetic tRNA for arginine translation at a single codon, successfully demonstrating the recoding of four sense codons to ncAAs ().
These tRNA manipulation strategies are able to free a large number of sense codons for efficient ncAA incorporation which are unattainable via stop codon suppression. Nonetheless, limitations still exist. For tRNA pool replacement, only 48 synthetic tRNAs were shown functional in CFPS, and the complete synthetic tRNA substitution pool was not achieved, which may hamper some specific artificial codon tables (). For specific tRNA elimination, the tRNAArg-specific tRNase (colicin D) method was limited by tRNase deficiency and could not be adopted more widely, while the tRNA antisense oligonucleotides may be a potential powerful tool for researchers.
Amino Acid Replacement
Due to the relaxed amino acid specificity of aaRS, a few ncAAs that are structurally similar to canonical amino acids can be charged to native tRNAs by corresponding aaRS. Examples include selenomethionine (), fluorinated tryptophan analogs (), chlorinated tyrosine analogs (Singh-Blom et al., 2014), 4-18F-fluoro-L-proline and 3,4-dihydroxy-l-phenylalanine (). Thus, structurally similar ncAAs can be incorporated in place of the corresponding native amino acids. In vivo, a few nutrient deficient strains lacking the specific amino acid biosynthesis enzymes have been constructed and cultured with supplementation of ncAAs for artificial protein expression (; ). However, ncAAs are toxic to the host strain because they will also be incorporated into essential endogenous proteins, resulting in a low growth rate and low protein yield. Moreover, residues of the corresponding canonical amino acid added during the preculture will also compete with the ncAA, leading to partially native protein.
Recently, CFPS was suggested to overcome these defects in amino acid analog incorporation. Even a detailed video protocol has been posted online (Worst et al., 2016). A cell extract of a nutrient deficient strain lacking the specific amino acid biosynthesis enzymes was prepared, followed by multiple diafiltration processes to remove all amino acids. The specific ncAA and 19 other canonical amino acids were added to the CFPS reaction for uncompetitive ncAA incorporation (Singh-Blom et al., 2014; Figure 2D). For instance, L-DOPA, a tyrosine substitute, was incorporated into protein with almost eight times higher efficiency than competitive systems (). The highly toxic arginine analog canavanine was also firstly incorporated into proteins in a tyrosine-replaced CFPS system (Worst et al., 2015).
This amino acid replacement CFPS method has been a cost-effective and simple alternative to ncAA incorporation methodologies without requiring engineered aaRS or tRNAs. However, owing to the loss of replaced canonical amino acids, various potential applications, which need the 20 canonical amino acids, are limited in this method. What’s more, although the specific amino acid biosynthesis enzymes had been knock out in cell-free strains, which avoided other amino acids generating the omitted amino acid to make incorrect incorporations. The omitted amino acid may still be generated from metabolic process in cell extract, such as degradation of endogenous proteins. This problem may be solved by some protease-deficient strains in future studies.
Incorporation of Multiple Different ncAAs
In addition to the incorporation of single ncAAs, the incorporation of multiple different ncAAs into the same protein has been achieved in vivo and in vitro, widely expanding the ability to engineer artificial proteins. By repeating ncAA reassigned codons in template, it is accessible to incorporate a single type ncAA into multiple different locations without methodological modification (; ). On the countrary, efficiently incorporating multiple different ncAAs into a single protein requires method improvements and modifications. So this section will focus on the emerging methods of multiple different ncAAs incorporation into a single protein. However, in vivo methods mainly relied on stop codon repression of the cell protein expression machine, leading to an undistinguished product yield due to the competition of peptide release factors (Wan et al., 2010; ; Wang et al., 2014; Venkat et al., 2018). Only one release factor has been deleted, because the other peptide release factor must be retained for translational termination in cells. Consequently, the RF1-deficient strains, such as C321.ΔA, are currently the most appropriate host strain for reducing competition during the incorporation of multiple ncAAs (Zheng et al., 2018). Although up to three different ncAAs have been incorporated into the same protein in the C321.ΔA strain, the competition between ncAAs and peptide RF2 still had negative effects in cells ().
Recently, cell extracts of RF1-deficient strains were also utilized in a CFPS system for efficient and modular artificial protein expression with multiple different ncAAs, but partial competition was still present, similar to the cells (; Ozer et al., 2017; ). Further, several total competition-removing CFPS methods were developed using different strategies. For instance, combined tRNA-specific affinity chromatography with stop codon repression in RF1-deficient strains for dual protein fluorescent labeling by incorporating AzF and BPFL-Cys into a single protein. This opens up the possibility of combining approaches at different levels to engineer proteins more freely.
Translation Factors Engineering
Various factors play important role in protein translation as well, especially in ncAA incorporation. These translation factors are also engineered to facilitate efficient ncAA incorporation. In this part, engineering achievement of elongation factor Tu (EF-Tu), ribosome and aaRS/tRNA pairs are summarized and discussed.
EF-Tu
EF-Tu is crucial in translation elongation phase, which is abundant in E. coli (). EF-Tu binds aminoacyl-tRNA and delivery them to the ribosome for peptide elongation. However, EF-Tu may not efficiently bind to ncAA with macromolecular or negatively charged groups, leading to ineffective incorporation (; ). Thus far, many efforts had been made to improve EF-Tu in ncAA incorporation by engineering the amino acid binding domain.
With evolution of the binding domain in EF-Tu, ncAAs such as phosphoserine, phosphotyrosine, selenocysteine, pyrenylalanine, and p-azido-phenylalanine, were efficiently incorporated into peptide. Some ncAAs carrying negative charged phosphorylation side chain are hard to be recognized by wild type EF-Tu. Therefore, mutant EF-Tu (H67R, E216N, D217G, F219Y, T229S, and N274W) was developed to efficiently incorporated phosphoserine into peptide (Park et al., 2011) and milligram of protein with phosphoserine incorporation was obtained in cell-free system extracted from strain C321.ΔA (Oza et al., 2015). Similarly, the EF-Tu variant (E216V, D217G, and F219G) was also successfully selected for phosphotyrosine incorporation (). And selenocysteine, another negatively charged amino acid, was also efficiently recognized by EF-Tu variant (H67Y, Q98Q, E216D, D217R, and N274R) (). developed EF-Tu mutants (E215A and D216A), in which the binding pocket of aminoacyl-tRNA was enlarged, to improve the binding of ncAAs carrying bulky side chain and this system successfully worked with ncAAs of L-1-pyrenylalanine, L-2-pyrenylalanine, and DL-2-anthraquinonylalanine as well. Incorporation of p-azido-phenylalanine was assisted by EF-Tu with mutant binding domain (S65A, D216A, and V274A) (). Although the function of these EF-Tu variants has been proved in vivo, it is easy to applied them in CFPS by either direct addition of purified EF-Tu variants protein or co-expression with other endogenous wild-type translation factors in cell. For instance, protein with phosphoserine incorporation was synthesized to milligram in CFPS with engineered EF-Tu (Oza et al., 2015).
Ribosome
Besides the normal proteinogenic amino acids, wild-type ribosome is also able to accept some analogs of L-α-amino acids (). Nonetheless, ncAAs with modified chemical backbone such as partial D-amino acids were incompatible with the wild-type translation machinery (). Modification of the peptidyl transferase center on ribosomal 50S subunit has high potential to enhance special ncAAs incorporation. For instance, the mutant 23s rRNA mutations (region of 2447–2451, 2457–2462, 2057–2063, and 2502–2507) allowed efficient peptidyl transfer of D-amino acids or β-amino acids, such as D-methionine, D-phenylalanine (, ), β-alanine and β-phenylalanine (; ). Interestingly, mutant 16S rRNA (A238U, G849U, G1175U, G1516U) was identified as well with improved activity for selenocysteine incorporation (Thyer et al., 2013). Moreover, several novel features have been evolved in ribosome to improve ncAA incorporation. Wang et al. (2007) developed an orthogonal ribosome with a decreased functional interaction with RF1 and improved amber codon suppression. Another orthogonal ribosome was developed for efficient quadruplet codon suppression (Neumann et al., 2010). Engineered ribosome may bring the risk of losing cell viability especially under overexpression (, ). Therefore, specially designed orthogonal ribosome may be the good solution, by which ncAA incorporation could be separated from endogenous translation and minimize the influence on cell viability.
Evolution of aaRS/tRNA Pairs
Aminoacylation is the key procedure for orthogonality of tRNA and corresponding amino acids. Thus far, a few of specific aaRS/tRNA pairs were developed, such as the PylRS/tRNA pair for lysine, phenylalanine and pyrrolysine analogs from Methanosarcina spp. (Polycarpo et al., 2006; ; Wang Y.S. et al., 2012), Methanococcus jannaschii and acetivorans TyrRS/tRNA pairs for tyrosine analogs (), Methanococcus maripaludis SepRS/tRNA pair for phosphoserine (Rogerson et al., 2015), Saccharomyces cerevisiae PheRS/tRNA pair for phenylalanine and alanine analogs (), Saccharomyces cerevisiae TrpRS/tRNA pair for tryptophan and alanine analogs (), Desulfitobacterium hafniense PylRS/tRNA for lysine analogs and Pyrococcus horikoshii ProRS/tRNA for proline analogs ().
However, the slow incorporation rate of nnAAs charged anminoacyl-tRNA leads to increased misincorporation of the endogenous aminoacyl-tRNA, inserting undesired canonical amino acid (O’Donoghue et al., 2012). Additionally, the site-specific incorporation requires accurate aminoacylation reaction between ncAA and its partner tRNA. Thus, directed evolution was applied to evolve efficient and accurate aaRS/tRNA pairs, including phage-assisted continuous evolution (PACE) (), compartmentalized partnered replication (CPR) (), parallel positive selection combined with deep sequencing and tRNA Extension (tREX) assisted with computationally identification (Zhang et al., 2017; ). And improved efficiency and specificity have been demonstrated for aaRS/tRNA pairs of Nε-Boc-L-lysine (BocK), Nε-acetyl-L-lysine (AcK) (), p-azido-L-phenylalanine (pAzF) (), 3-iodo-L-tyrosine (Oki et al., 2008). O-methyl-L-tyrosine (), and so on. However, the degree of the orthogonality of these evolved aaRS/tRNA pairs is crucial for in vivo application. All of these evolved aaRS/tRNA pairs could also be applied in CFPS by either directly addition of purified protein or pre-expression in the cell. And, the activity of orthogonal aaRS/tRNA could be improved by accurately adjusting its relative concentration in cell-free system.
Novel ncAAs and in vitro Aminoacylation Methods for CFPS
Without limitations of cell viability and membrane barrier, CFPS allows the direct addition of specific aminoacyl-tRNA to participate in ribosomal translation, in which the aminoacyl-tRNA is pre-synthesized before the CFPS reaction. By decoupling aminoacylation and translation in CFPS, several limitations can be overcome. On the one hand, because the ncAA aminoacylation reaction is physically separated from endogenous reactions, the orthogonality of aaRS is unnecessary, so that time-consuming enzyme evolution can be avoided and more ncAAs can be utilized by in vitro aminoacylation (Urbanek et al., 2018). On the other hand, more chemical and enzymatic methods can be utilized to generate aminoacyl-tRNAs, breaking the limitation that only analogs of L-α-amino acids can be charged by aaRS (Ninomiya et al., 2003; ). Through in vitro aminoacylation methods, orthogonality requirement of aminoacylation process can be avoided, in which tRNA can only be charged by the only amino acid in vitro. But after translation, the released tRNA may be recharged by endogenous aaRS if it is not orthogonal to endogenous system, possibly resulting in incorrect incorporation. Thus, orthogonality evolution of aminoacylation factors can be skipped to save cost, while orthogonal tRNA is needed to achieve accurate ncAAs incorporation. Recently, several novel ncAAs were successfully incorporated into protein by such in vitro aminoacylation methods, including D-α-amino acids (), β-amino acids (), γ-amino acids (Ohshiro et al., 2011), N-alkylated-α-amino acids (), N-acylated-α-amino acids (), α-hydroxy acids (Ohta et al., 2008), α-benzoic acids and even foldamers (; Rogers et al., 2018; Figure 3).
FIGURE 3
These novel ncAAs widely expand the ability to engineer artificial proteins with novel features, which may increase the proteolytic stability, membrane permeability, and conformational rigidity of the peptide. For instance, the thioether macrocyclic peptides incorporated with D-amino acids could provide high serum stability due to structural difference and protease resistance (). And β-amino acids were considered as the potential building blocks of peptide analogs for pharmaceutical uses with the improved stability against proteolysis (). Cyclic peptide antagonists containing N-alkylated-α-amino acids also showed more membrane-permeable and stable to proteolysis (; ). The foldamers may potentially be highly water-soluble and possess cell-penetrating properties (). However, more applications are limited by preparation method of peptide with novel ncAAs. In this part, novel amino acids and different in vitro aminoacylation methods for CFPS platforms will be summarized and discussed.
In vitro Aminoacylation by aaRS
Utilizing the relaxed amino acid specificity of some aaRS, a few analogs of L-α-amino acids can be directly charged to tRNAs by aaRS (; Figure 4A). When aminoacylation and translation are conducted in the same system, in order to avoid competition between amino acids in the same aaRS/tRNA pair, the corresponding canonical amino acid should be removed to safeguard the orthogonality of the translation machine. Via pre-aminoacylation with ncAAs by aaRS, not only any codon, including stop codons, can be reassigned to a ncAA with a defined aminoacyl-tRNA, but also more efficient ncAA incorporation can be realized by optimizing additive concentrations (Urbanek et al., 2020). For instance, the general method for the expression of isotopically labeled proteins relies on aaRS charging isotopically labeled amino acids. With [15N,13C]-glutamine pre-charged by yeast glutaminyl-tRNA synthetase, homogeneous protein was obtained for high-dimensional NMR spectroscopy (Urbanek et al., 2018).
FIGURE 4
Another method is the chemical modification of side chains in canonical aminoacyl-tRNAs after normal aminoacylation by aaRS, generating ncAA aminoacyl-tRNAs to participate in translation (Figure 4A). Several side chains were successfully modified in canonical aminoacyl-tRNAs, generating moieties such as phenyllactyl amino acids (), N-methyl amino acids (), glycosyl amino acids (), fluorescence labeled amino acids and BODIPY labeled amino acids ().
Compared to in vivo methods relying on introducing orthogonal aaRS/tRNA pairs into cells, in vitro aminoacylation by aaRS physically separates the ncAA aminoacylation reaction from endogenous reactions, avoiding orthogonality requirement of aaRS in ncAA aminoacylation process. The cost and time-consuming aaRS evolution can be skipped. And available ncAAs are expanded without orthogonality. However, after the dehydration condensation reaction in ribosome, the released tRNA could be recharged with unwished amino acids if it is not orthogonal to endogenous aaRS, leading to misincorporations. For precise and efficient ncAA incorporation, the corresponding tRNA needs to be orthogonal to endogenous systems. What’s more, the available specter of ncAAs is still largely limited to analogs of L-α-amino acids.
Chemical Aminoacylation
Chemical aminoacylation is a versatile classical strategy for aminoacyl-tRNA synthesis in vitro (; Figure 4B). Although several improvements have been made, the general process remained consistent (; Noren et al., 1989; Ninomiya et al., 2003; ; ). The amino acid with appropriate protecting groups is chemically charged to the 3′-OH of pCpA or pdCpA, which was chemical synthesized. Subsequently, the corresponding truncated tRNA, lacking two bases at the 3′-terminal, is ligated with aminoacyl-pCpA (or pdCpA) by T4 RNA ligase to generate the complete aminoacyl-tRNA. In theory, this method can be used to load any tRNA with any desired amino acid, such as N-acetyl amino acids (Yamanaka et al., 2004), glycosylated serine, and tyrosine (), N-methyl and N-nitro arginine (), citrulline (), homoarginine, and isotopically labeled canonical amino acids (Peuker et al., 2016).
In theory, the greatest strength of this method is that any desired amino acid can be charged to any tRNA. However, the combination of chemical synthesis with enzymatic ligation is labor-intensive and it is challenging to produce homogeneous aminoacyl-tRNAs. Especially the primary by-product, self-ligated tRNA, is unavoidably generated by T4 RNA ligase, leading to inefficient synthesis, which may be avoided in future researches.
Ribozyme Aminoacylation
In addition to aaRS and chemical aminoacylation, Suga et al. evolved small ribozymes (44–46 nt) that synthesize aminoacyl-tRNAs. These so-called flexizymes can charge tRNAs with amino acids with an activated carboxyl group (; ). This activated carboxyl group and the 3′-terminal NCCA sequence of tRNA are crucial recognized sites of the flexizyme catalytic domain (Xiao et al., 2008). Therefore, in theory, the ncAA can be reassigned to any codon. Recently, some flexizyme variants were artificially evolved to accept amino acids with different activated carboxyl groups (). The aFx, dFx, and eFx flexizymes are three widely used representatives, respectively recognizing amino acids carrying an activated amino-derivatized benzyl thioester (ABT), dinitrobenzyl ester (DBE) or chlorobenzyl ester (CBE) (Niwa et al., 2009; Passioura and Suga, 2013; Figure 4C). More recently, more than thirty activated groups were verified to be accessible to flexizyme aminoacylation, significantly expanding the range of available amino acids ().
As an emerging method, flexizyme aminoacylation has been applied as a versatile strategy for the incorporation of a great many ncAAs. The only two limitations imposed on the amino acids are the feasibility to activate the carboxyl with a certain group and chemical stability during the aminoacylation process. In fact, different ncAAs have been utilized even with multiple incorporations, including D-α-amino acids (), β-amino acids (), γ-amino acids (Ohshiro et al., 2011), α-hydroxy acids (Ohta et al., 2008), α-benzoic acids (), N-alkyl-L-α-amino acids (), N-methyl-L-α-amino acids (), and even foldamers (Rogers et al., 2018). However, the efficiency of flexizyme aminoacylation varies depending on the ncAAs with a wide range of 17–91%, which can only be optimized empirically, since there are no established design rules (). Moreover, the ribosome incorporation capacity of ncAA aminoacyl-tRNAs also ranges from zero to high efficiency. For instance, only eight of nineteen D-α-amino acids showed highly efficient incorporation, while low efficiencies were observed in four D-α-amino acids and the other was incompatible with the ribosome (, ). Henceforth, more versatile aminoacylation and translation techniques are worth developing to satisfy the increasing demand for ncAA incorporation.
Conclusion and Prospects
Cell-free protein synthesis has emerged as a powerful platform for engineering the genetic code with its unique advantages allowing the efficient and extensive incorporation of ncAAs, which were summarized in this review. To improve the efficiency and yield of artificial proteins, several strategies have been presented to remove ncAA competitors at different levels, including genome engineering, elimination of peptide release factors, tRNA manipulation and amino acid replacement. The pros and cons of these strategies have been discussed in detail above. By combining methods at different levels, multiple codons, including sense and nonsense codons, could be simultaneously reassigned to different ncAAs without endogenous competitors, contributing to more flexible artificial protein synthesis (). To enhance ncAA incorporation, several translation factors have been engineered for improvement, such as EF-Tu, ribosome and aaRS/tRNA pairs. At the same time, CFPS is compatible with in vitro aminoacylation methods, which can supply a wider range of novel and unique ncAAs for artificial protein research. Compared with aaRS and chemical aminoacylation methods, flexizymes have been developed into a highly versatile and efficient approach for aminoacyl-tRNA synthesis, with many recent studies confirming its expansion. By emphasizing these crucial techniques for ncAA incorporation via CFPS, this review is intended to provide a bridge between current technologies and future directions in this rapidly developing field.
Looking forward, these tools have the potential to be applied in various emerging fields, such as antibody-drug conjugates, protein labeling, peptide-based materials and so on (; Stech et al., 2017; Suga, 2018). Especially in enzyme activity improvement, several efforts have been made with significant influence. For instance, enzyme phosphorylation is a key modification for protein activity, which may occur on tyrosines, threonines and serines. Phosphotyrosine and phosphothreonine were used to activate vasodilator-stimulated phosphoprotein (VASP) and the nicotinic acetyl choline receptor (nAChR) (Rothman et al., 2005). With phosphoserine incorporation, several homogeneous phosphorylated enzymes have been expressed, such as human MEK1 kinase, human Stimulator of Interferon Genes (STING), and Bcl2-associated agonist of cell death (BAD) (Oza et al., 2015; Zhu et al., 2019). Furthermore, methylhistidine also showed important activating effects in the enzyme catalytic center of fluorescent proteins, heme enzymes, and metalloenzymes (Xiao et al., 2014; ; Ortmayer et al., 2020). Acetyllysine and methyllysine play a crucial role in the control of chromatin and epigenetic programs by histones, which has been demonstrated by site-specific incorporation with in vitro aminoacylation in CFPS (Sterner and Berger, 2000; Yanagisawa et al., 2014; Wakamori et al., 2015; Xiong et al., 2016). In addition, numerous unclear modifications of amino acids in the enzymatic active center need to be investigated in the future, such as hydroxylation, glycosylation, sulfation, and amidation. Overall, this review hopes to assist researchers in choosing suitable methods to incorporate ncAAs efficiently and easily using CFPS, hopefully inspiring breakthroughs of ncAA techniques and applications in the future.
Statements
Author contributions
YW gathered the information, drafted the original manuscript, and designed the figures. ZW contributed to literature collection. HQ conceived the presented idea and supervised the work. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the National Key R&D Program of China (Grant No. 2019YFA0904103) and the National Science Foundation of China (Grant Nos. 21476167, 21778039, and 21621004).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbdelkaderE. H.FeintuchA.YaoX.AdamsL. A.AurelioL.GrahamB.et al (2015). Protein conformation by EPR spectroscopy using gadolinium tags clicked to genetically encoded p-azido-L-phenylalanine.Chem. Commun.5115898–15901. 10.1039/c5cc07121f
2
AdachiJ.KatsuraK.SekiE.TakemotoC.ShirouzuM.TeradaT.et al (2019). Cell-free protein synthesis using S30 extracts from Escherichia coli RFzero strains for efficient incorporation of non-natural amino acids into proteins.Int. J. Mol. Sci.20:492. 10.3390/ijms20030492
3
AgafonovD. E.HuangY.GroteM.SprinzlM. (2005). Efficient suppression of the amber codon in E. coli in vitro translation system.FEBS Lett.5792156–2160. 10.1016/j.febslet.2005.03.004
4
AlbayrakC.SwartzJ. R. (2014). Direct polymerization of proteins.ACS Synth. Biol.3353–362. 10.1021/sb400116x
5
AmiramM.HaimovichA. D.FanC.WangY. S.AerniH. R.NtaiI.et al (2015). Evolution of translation machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids.Nat. Biotechnol.331272–1279. 10.1038/nbt.3372
6
BaeriswylV.HeinisC. (2013). Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases.Protein Eng. Des. Sel.2681–89. 10.1093/protein/gzs085
7
BashiruddinN. K.SugaH. (2015). Construction and screening of vast libraries of natural product-like macrocyclic peptides using in vitro display technologies.Curr. Opin. Chem. Biol.24131–138. 10.1016/j.cbpa.2014.11.011
8
BhatS. V.NagasampagiB. A.SivakumarM. (2005). Chemistry of Natural Products.Berlin: Springer Science & Business Media.
9
BreuillardC.BonhommeS.CoudercR.CynoberL.De BandtJ. P. (2015). In vitro anti-inflammatory effects of citrulline on peritoneal macrophages in Zucker diabetic fatty rats.Br. J. Nutr.113120–124. 10.1017/S0007114514002086
10
BrysonD. I.FanC.GuoL. T.MillerC.SollD.LiuD. R. (2017). Continuous directed evolution of aminoacyl-tRNA synthetases.Nat. Chem. Biol.131253–1260. 10.1038/nchembio.2474
11
BudisaN.PalP. P.AlefelderS.BirleP.KrywcunT.RubiniM.et al (2004). Probing the role of tryptophans in aequorea victoria green fluorescent proteins with an expanded genetic code.Biol. Chem.385191–202. 10.1515/BC.2004.038
12
BundyB. C.FranciszkowiczM. J.SwartzJ. R. (2008). Escherichia coli-based cell-free synthesis of virus-like particles.Biotechnol. Bioeng10028–37. 10.1002/bit.21716
13
CallesJ.JusticeI.BrinkleyD.GarciaA.EndyD. (2019). Fail-safe genetic codes designed to intrinsically contain engineered organisms.Nucleic Acids Res.4710439–10451. 10.1093/nar/gkz745
14
CervettiniD.TangS.FriedS. D.WillisJ. C. W.FunkeL. F. H.ColwellL. J.et al (2020). Rapid discovery and evolution of orthogonal aminoacyl-tRNA synthetase-tRNA pairs.Nat. Biotechnol.10.1038/s41587-020-0479-2
15
ChatterjeeA.SunS. B.FurmanJ. L.XiaoH.SchultzP. G. (2013a). A versatile platform for single- and multiple-unnatural amino acid mutagenesis in Escherichia coli.Biochemistry521828–1837. 10.1021/bi4000244
16
ChatterjeeA.XiaoH.YangP. Y.SoundararajanG.SchultzP. G. (2013b). A tryptophanyl-tRNA synthetase/tRNA pair for unnatural amino acid mutagenesis in E. coli.Angew. Chem. Int. Ed. Engl.525106–5109. 10.1002/anie.201301094
17
ChatterjeeA.XiaoH.SchultzP. G. (2012). Evolution of multiple, mutually orthogonal prolyl-tRNA synthetase/tRNA pairs for unnatural amino acid mutagenesis in Escherichia coli.Proc. Natl. Acad. Sci. U.S.A.10914841–14846. 10.1073/pnas.1212454109
18
ChatterjeeJ.GilonC.HoffmanA.KesslerH. (2008). N-methylation of peptides: a new perspective in medicinal chemistry.Acc. Chem. Res.411331–1342. 10.1021/ar8000603
19
ChemlaY.OzerE.ShafermanM.ZaadB.DandelaR.AlfontaL. (2019). Simplified methodology for a modular and genetically expanded protein synthesis in cell-free systems.Synth. Syst. Biotechnol.4189–196. 10.1016/j.synbio.2019.10.002
20
ChinJ. W. (2017). Expanding and reprogramming the genetic code.Nature55053–60. 10.1038/nature24031
21
ChoudhuryA. K.GolovineS. Y.DedkovaL. M.HechtS. M. (2007). Synthesis of proteins containing modified arginine residues.Biochemistry464066–4076. 10.1021/bi062042r
22
CuiZ.MureevS.PolinkovskyM. E.TnimovZ.GuoZ.DurekT.et al (2017). Combining sense and nonsense codon reassignment for site-selective protein modification with unnatural amino acids.ACS Synth. Biol.6535–544. 10.1021/acssynbio.6b00245
23
CuiZ.SteinV.TnimovZ.MureevS.AlexandrovK. (2015). Semisynthetic tRNA complement mediates in vitro protein synthesis.J. Am. Chem. Soc.1374404–4413. 10.1021/ja5131963
24
CuiZ.WuY.MureevS.AlexandrovK. (2018). Oligonucleotide-mediated tRNA sequestration enables one-pot sense codon reassignment in vitro.Nucleic Acids Res.466387–6400. 10.1093/nar/gky365
25
DedkovaL. M.FahmiN. E.GolovineS. Y.HechtS. M. (2003). Enhanced D-amino acid incorporation into protein by modified ribosomes.J. Am. Chem. Soc.1256616–6617. 10.1021/ja035141q
26
DedkovaL. M.FahmiN. E.GolovineS. Y.HechtS. M. (2006). Construction of modified ribosomes for incorporation of D-amino acids into proteins.Biochemistry4515541–15551. 10.1021/bi060986a
27
DedkovaL. M.HechtS. M. (2019). Expanding the scope of protein synthesis using modified ribosomes.J. Am. Chem. Soc.1416430–6447. 10.1021/jacs.9b02109
28
Des SoyeB. J.GerbasiV. R.ThomasP. M.KelleherN. L.JewettM. C. (2019). A highly productive, one-pot cell-free protein synthesis platform based on genomically recoded Escherichia coli.Cell Chem. Biol.261743.e9–1754.e9. 10.1016/j.chembiol.2019.10.008
29
DoiY.OhtsukiT.ShimizuY.UedaT.SisidoM. (2007). Elongation factor Tu mutants expand amino acid tolerance of protein biosynthesis system.J. Am. Chem. Soc.12914458–14462. 10.1021/ja075557u
30
DoppB. J. L.TamievD. D.ReuelN. F. (2019). Cell-free supplement mixtures: elucidating the history and biochemical utility of additives used to support in vitro protein synthesis in E. coli extract.Biotechnol. Adv.37246–258. 10.1016/j.biotechadv.2018.12.006
31
DumasA.LercherL.SpicerC. D.DavisB. G. (2015). Designing logical codon reassignment - Expanding the chemistry in biology.Chem. Sci.650–69. 10.1039/c4sc01534g
32
EllefsonJ. W.MeyerA. J.HughesR. A.CannonJ. R.BrodbeltJ. S.EllingtonA. D. (2014). Directed evolution of genetic parts and circuits by compartmentalized partnered replication.Nat. Biotechnol.3297–101. 10.1038/nbt.2714
33
EsveltK. M.CarlsonJ. C.LiuD. R. (2011). A system for the continuous directed evolution of biomolecules.Nature472499–503. 10.1038/nature09929
34
FahmiN. E.DedkovaL.WangB.GolovineS.HechtS. M. (2007). Site-specific incorporation of glycosylated serine and tyrosine derivatives into proteins.J. Am. Chem. Soc.1293586–3597. 10.1021/ja067466n
35
FahnestockS.RichA. (1971). Ribosome-catalyzed polyester formation.Science173340–343. 10.1126/science.173.3994.340
36
FanC.IpK.SollD. (2016). Expanding the genetic code of Escherichia coli with phosphotyrosine.FEBS Lett.5903040–3047. 10.1002/1873-3468.12333
37
FujinoT.GotoY.SugaH.MurakamiH. (2013). Reevaluation of the D-amino acid compatibility with the elongation event in translation.J. Am. Chem. Soc.1351830–1837. 10.1021/ja309570x
38
FujinoT.GotoY.SugaH.MurakamiH. (2016). Ribosomal synthesis of peptides with multiple β-amino acids.J. Am. Chem. Soc.1381962–1969. 10.1021/jacs.5b12482
39
FuranoA. V. (1975). Content of elongation factor Tu in Escherichia coli.Proc. Natl. Acad. Sci. U.S.A.724780–4784. 10.1073/pnas.72.12.4780
40
GanF.LiuR.WangF.SchultzP. G. (2018). Functional replacement of histidine in proteins to generate noncanonical amino acid dependent organisms.J. Am. Chem. Soc.1403829–3832. 10.1021/jacs.7b13452
41
GanR.PerezJ. G.CarlsonE. D.NtaiI.IsaacsF. J.KelleherN. L.et al (2017). Translation system engineering in Escherichia coli enhances non-canonical amino acid incorporation into proteins.Biotechnol. Bioeng1141074–1086. 10.1002/bit.26239
42
GfellerD.MichielinO.ZoeteV. (2013). SwissSidechain: a molecular and structural database of non-natural sidechains.Nucleic Acids Res.41D327–D332. 10.1093/nar/gks991
43
GilliesE. R.DeissF.StaedelC.SchmitterJ. M.HucI. (2007). Development and biological assessment of fully water-soluble helical aromatic amide foldamers.Angew. Chem. Int. Ed.464081–4084. 10.1002/anie.200700301
44
GotoY.KatohT.SugaH. (2011). Flexizymes for genetic code reprogramming.Nat. Protoc.6779–790. 10.1038/nprot.2011.331
45
HaradaR.FurumotoS.YoshikawaT.IshikawaY.ShibuyaK.OkamuraN.et al (2016). Synthesis and characterization of (1)(8)F-Interleukin-8 using a cell-free translation system and 4-(1)(8)F-Fluoro-L-Proline.J. Nucl. Med.57634–639. 10.2967/jnumed.115.162602
46
HarunaK.AlkazemiM. H.LiuY.SollD.EnglertM. (2014). Engineering the elongation factor Tu for efficient selenoprotein synthesis.Nucleic Acids Res.429976–9983. 10.1093/nar/gku691
47
HechtS. M.AlfordB. L.KurodaY.KitanoS. (1978). “Chemical aminoacylation” of tRNA’s.J. Biol. Chem.2534517–4520.
48
HecklerT. G.ChangL. H.ZamaY.NakaT.ChorghadeM. S.HechtS. M. (1984). T4 RNA ligase mediated preparation of novel “chemically misacylated” tRNAPheS.Biochemistry231468–1473. 10.1021/bi00302a020
49
HongS. H.KwonY. C.MartinR. W.Des SoyeB. J.de PazA. M.SwongerK. N.et al (2015). Improving cell-free protein synthesis through genome engineering of Escherichia coli lacking release factor 1.Chembiochem16844–853. 10.1002/cbic.201402708
50
HongS. H.NtaiI.HaimovichA. D.KelleherN. L.IsaacsF. J.JewettM. C. (2014). Cell-free protein synthesis from a release factor 1 deficient Escherichia coli activates efficient and multiple site-specific nonstandard amino acid incorporation.ACS Synth. Biol.3398–409. 10.1021/sb400140t
51
HuC.ChanS. I.SawyerE. B.YuY.WangJ. (2014). Metalloprotein design using genetic code expansion.Chem. Soc. Rev.436498–6510. 10.1039/c4cs00018h
52
IijimaI.HohsakaT. (2009). Position-specific incorporation of fluorescent non-natural amino acids into maltose-binding protein for detection of ligand binding by FRET and fluorescence quenching.Chembiochem10999–1006. 10.1002/cbic.200800703
53
Ikeda-BokuA.OhnoS.HibinoY.YokogawaT.HayashiN.NishikawaK. (2013). A simple system for expression of proteins containing 3-azidotyrosine at a pre-determined site in Escherichia coli.J. Biochem.153317–326. 10.1093/jb/mvs153
54
ItaliaJ. S.AddyP. S.EricksonS. B.PeelerJ. C.WeerapanaE.ChatterjeeA. (2019). Mutually orthogonal nonsense-suppression systems and conjugation chemistries for precise protein labeling at up to three distinct sites.J. Am. Chem. Soc.1416204–6212. 10.1021/jacs.8b12954
55
JabarS.AdamsL. A.WangY.AurelioL.GrahamB.OttingG. (2017). Chemical tagging with tert-Butyl and trimethylsilyl groups for measuring intermolecular nuclear overhauser effects in a large protein-ligand complex.Chemistry2313033–13036. 10.1002/chem.201703531
56
JohnsonD. B.WangC.XuJ.SchultzM. D.SchmitzR. J.EckerJ. R.et al (2012). Release factor one is nonessential in Escherichia coli.ACS Chem. Biol.71337–1344. 10.1021/cb300229q
57
JohnsonD. B.XuJ.ShenZ.TakimotoJ. K.SchultzM. D.SchmitzR. J.et al (2011). RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites.Nat. Chem. Biol.7779–786. 10.1038/nchembio.657
58
KarimA. S.JewettM. C. (2016). A cell-free framework for rapid biosynthetic pathway prototyping and enzyme discovery.Metab. Eng.36116–126. 10.1016/j.ymben.2016.03.002
59
KatayamaH.NozawaK.NurekiO.NakaharaY.HojoH. (2012). Pyrrolysine analogs as substrates for bacterial pyrrolysyl-tRNA synthetase in vitro and in vivo.Biosci. Biotechnol. Biochem.76205–208. 10.1271/bbb.110653
60
KatohT.IwaneY.SugaH. (2017a). Logical engineering of D-arm and T-stem of tRNA that enhances d-amino acid incorporation.Nucleic Acids Res.4512601–12610. 10.1093/nar/gkx1129
61
KatohT.TajimaK.SugaH. (2017b). Consecutive elongation of D-Amino acids in translation.Cell Chem. Biol.2446–54. 10.1016/j.chembiol.2016.11.012
62
KatohT.SugaH. (2018). Ribosomal incorporation of consecutive beta-Amino acids.J. Am. Chem. Soc.14012159–12167. 10.1021/jacs.8b07247
63
KatohT.SugaH. (2019). Engineering translation components improve incorporation of exotic amino acids.Int. J. Mol. Sci.20:522. 10.3390/ijms20030522
64
KawakamiT.IshizawaT.MurakamiH. (2013). Extensive reprogramming of the genetic code for genetically encoded synthesis of highly N-alkylated polycyclic peptidomimetics.J. Am. Chem. Soc.13512297–12304. 10.1021/ja405044k
65
KawakamiT.MurakamiH.SugaH. (2008). Messenger RNA-programmed incorporation of multiple N-methyl-amino acids into linear and cyclic peptides.Chem. Biol.1532–42. 10.1016/j.chembiol.2007.12.008
66
KawakamiT.OgawaK.HattaT.GoshimaN.NatsumeT. (2016). Directed evolution of a cyclized peptoid-peptide chimera against a cell-free expressed protein and proteomic profiling of the interacting proteins to create a protein-protein interaction inhibitor.ACS Chem. Biol.111569–1577. 10.1021/acschembio.5b01014
67
KigawaT.Yamaguchi-NunokawaE.KodamaK.MatsudaT.YabukiT.MatsudaN.et al (2002). Selenomethionine incorporation into a protein by cell-free synthesis.J. Struct. Funct. Genomics229–35. 10.1023/a:1013203532303
68
KightlingerW.DunckerK. E.RameshA.ThamesA. H.NatarajanA.StarkJ. C.et al (2019). A cell-free biosynthesis platform for modular construction of protein glycosylation pathways.Nat. Commun.10:5404. 10.1038/s41467-019-12024-9
69
KwiatkowskiM.WangJ.ForsterA. C. (2014). Facile synthesis of N-acyl-aminoacyl-pCpA for preparation of mischarged fully ribo tRNA.Bioconjug Chem.252086–2091. 10.1021/bc500441b
70
KwonI.LimS. I. (2015). Tailoring the substrate specificity of yeast phenylalanyl-tRNA synthetase toward a phenylalanine analog using multiple-site-specific incorporation.ACS Synth. Biol.4634–643. 10.1021/sb500309r
71
LajoieM. J.RovnerA. J.GoodmanD. B.AerniH. R.HaimovichA. D.KuznetsovG.et al (2013). Genomically recoded organisms expand biological functions.Science342357–360. 10.1126/science.1241459
72
LavickovaB.MaerklS. J. (2019). A simple, robust, and low-cost method to produce the PURE cell-free system.ACS Synth. Biol.8455–462. 10.1021/acssynbio.8b00427
73
LeeJ.SchwieterK. E.WatkinsA. M.KimD. S.YuH.SchwarzK. J.et al (2019). Expanding the limits of the second genetic code with ribozymes.Nat. Commun.10:5097. 10.1038/s41467-019-12916-w
74
LeeK. B.HouC. Y.KimC. E.KimD. M.SugaH.KangT. J. (2016). Genetic code expansion by degeneracy reprogramming of arginyl codons.Chembiochem171198–1201. 10.1002/cbic.201600111
75
LeeK.-H.CatherineC.KimD.-M. (2016). Enhanced production of unnatural amino acid-containing proteins in a cell-free protein synthesis system.J. Ind. Eng. Chem.3790–94. 10.1016/j.jiec.2016.03.008
76
LiuW.-Q.ZhangL.ChenM.LiJ. (2019). Cell-free protein synthesis: recent advances in bacterial extract sources and expanded applications.Biochem. Eng. J.141182–189. 10.1016/j.bej.2018.10.023
77
LodderM.WangB.HechtS. M. (2005). The N-pentenoyl protecting group for aminoacyl-tRNAs.Methods36245–251. 10.1016/j.ymeth.2005.04.002
78
LoschaK. V.HerltA. J.QiR.HuberT.OzawaK.OttingG. (2012). Multiple-site labeling of proteins with unnatural amino acids.Angew. Chem. Int. Ed. Engl.512243–2246. 10.1002/anie.201108275
79
LuY. (2017). Cell-free synthetic biology: engineering in an open world.Synth. Syst. Biotechnol.223–27. 10.1016/j.synbio.2017.02.003
80
MainiR.NguyenD. T.ChenS.DedkovaL. M.ChowdhuryS. R.Alcala-ToranoR.et al (2013). Incorporation of beta-amino acids into dihydrofolate reductase by ribosomes having modifications in the peptidyltransferase center.Bioorg. Med. Chem.211088–1096. 10.1016/j.bmc.2013.01.002
81
MartinR. W.Des SoyeB. J.KwonY. C.KayJ.DavisR. G.ThomasP. M.et al (2018). Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids.Nat. Commun.9:1203. 10.1038/s41467-018-03469-5
82
MatW. K.XueH.WongJ. T. (2010). Genetic code mutations: the breaking of a three billion year invariance.PLoS One5:e12206. 10.1371/journal.pone.0012206
83
MelnikovS. V.KhabibullinaN. F.MairhoferE.Vargas-RodriguezO.ReynoldsN. M.MicuraR.et al (2019). Mechanistic insights into the slow peptide bond formation with D-amino acids in the ribosomal active site.Nucleic Acids Res.472089–2100. 10.1093/nar/gky1211
84
Melo CzeksterC.RobertsonW. E.WalkerA. S.SollD.SchepartzA. (2016). In vivo biosynthesis of a beta-amino acid-containing protein.J. Am. Chem. Soc.1385194–5197. 10.1021/jacs.6b01023
85
MerrymanC.GreenR. (2004). Transformation of aminoacyl tRNAs for the in vitro selection of “drug-like” molecules.Chem. Biol.11575–582. 10.1016/j.chembiol.2004.03.009
86
MontclareJ. K.SonS.ClarkG. A.KumarK.TirrellD. A. (2009). Biosynthesis and stability of coiled-coil peptides containing (2S,4R)-5,5,5-trifluoroleucine and (2S,4S)-5,5,5-trifluoroleucine.Chembiochem1084–86. 10.1002/cbic.200800164
87
MorimotoJ.HayashiY.IwasakiK.SugaH. (2011). Flexizymes: their evolutionary history and the origin of catalytic function.Acc. Chem. Res.441359–1368. 10.1021/ar2000953
88
MukaiT.HayashiA.IrahaF.SatoA.OhtakeK.YokoyamaS.et al (2010). Codon reassignment in the Escherichia coli genetic code.Nucleic Acids Res.388188–8195. 10.1093/nar/gkq707
89
MukaiT.HoshiH.OhtakeK.TakahashiM.YamaguchiA.HayashiA.et al (2015). Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon.Sci. Rep.5:9699. 10.1038/srep09699
90
MukaiT.YanagisawaT.OhtakeK.WakamoriM.AdachiJ.HinoN.et al (2011). Genetic-code evolution for protein synthesis with non-natural amino acids.Biochem. Biophys. Res. Commun.411757–761. 10.1016/j.bbrc.2011.07.020
91
MurakamiH.OhtaA.AshigaiH.SugaH. (2006). A highly flexible tRNA acylation method for non-natural polypeptide synthesis.Nat. Methods3357–359. 10.1038/nmeth877
92
NarumiR.MasudaK.TomonagaT.AdachiJ.UedaH. R.ShimizuY. (2018). Cell-free synthesis of stable isotope-labeled internal standards for targeted quantitative proteomics.Synth. Syst. Biotechnol.397–104. 10.1016/j.synbio.2018.02.004
93
NeumannH.WangK.DavisL.Garcia-AlaiM.ChinJ. W. (2010). Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome.Nature464441–444. 10.1038/nature08817
94
NinomiyaK.KuritaT.HohsakaT.SisidoM. (2003). Facile aminoacylation of pdCpA dinucleotide with a nonnatural amino acid in cationic micelle.Chem. Commun.72242–2243. 10.1039/b306011j
95
NiwaN.YamagishiY.MurakamiH.SugaH. (2009). A flexizyme that selectively charges amino acids activated by a water-friendly leaving group.Bioorg. Med. Chem. Lett.193892–3894. 10.1016/j.bmcl.2009.03.114
96
NorenC. J.Anthony-CahillS. J.GriffithM. C.SchultzP. G. (1989). A general method for site-specific incorporation of unnatural amino acids into proteins.Science244182–188. 10.1126/science.2649980
97
O’DonoghueP.PratL.HeinemannI. U.LingJ.OdoiK.LiuW. R.et al (2012). Near-cognate suppression of amber, opal and quadruplet codons competes with aminoacyl-tRNAPyl for genetic code expansion.FEBS Lett.5863931–3937. 10.1016/j.febslet.2012.09.033
98
OgawaA.NishiT.SandoS.AoyamaY. (2005). In vitro selection of RNA aptamers for the Escherichia coli release factor 1.Nucleic Acids Symp. Ser.2005269–270. 10.1093/nass/49.1.269
99
OhshiroY.NakajimaE.GotoY.FuseS.TakahashiT.DoiT.et al (2011). Ribosomal synthesis of backbone-macrocyclic peptides containing gamma-amino acids.Chembiochem121183–1187. 10.1002/cbic.201100104
100
OhtaA.MurakamiH.SugaH. (2008). Polymerization of alpha-hydroxy acids by ribosomes.Chembiochem92773–2778. 10.1002/cbic.200800439
101
OhtakeK.SatoA.MukaiT.HinoN.YokoyamaS.SakamotoK. (2012). Efficient decoding of the UAG triplet as a full-fledged sense codon enhances the growth of a prfA-deficient strain of Escherichia coli.J. Bacteriol.1942606–2613. 10.1128/JB.00195-12
102
OkiK.SakamotoK.KobayashiT.SasakiH. M.YokoyamaS. (2008). Transplantation of a tyrosine editing domain into a tyrosyl-tRNA synthetase variant enhances its specificity for a tyrosine analog.Proc. Natl. Acad. Sci. U.S.A.10513298–13303. 10.1073/pnas.0803531105
103
OrtmayerM.FisherK.BasranJ.Wolde-MichaelE. M.HeyesD. J.LevyC.et al (2020). Rewiring the “Push-Pull” catalytic machinery of a heme enzyme using an expanded genetic code.ACS Catalysis102735–2746. 10.1021/acscatal.9b05129
104
OzaJ. P.AerniH. R.PirmanN. L.BarberK. W.Ter HaarC. M.RogulinaS.et al (2015). Robust production of recombinant phosphoproteins using cell-free protein synthesis.Nat. Commun.6:8168. 10.1038/ncomms9168
105
OzerE.ChemlaY.SchlesingerO.AviramH. Y.RivenI.HaranG.et al (2017). In vitro suppression of two different stop codons.Biotechnol. Bioeng.1141065–1073. 10.1002/bit.26226
106
ParkH. S.HohnM. J.UmeharaT.GuoL. T.OsborneE. M.BennerJ.et al (2011). Expanding the genetic code of Escherichia coli with phosphoserine.Science3331151–1154. 10.1126/science.1207203
107
PassiouraT.SugaH. (2013). Flexizyme-mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery.Chemistry196530–6536. 10.1002/chem.201300247
108
PeukerS.AnderssonH.GustavssonE.MaitiK. S.KaniaR.KarimA.et al (2016). Efficient isotope editing of proteins for site-directed vibrational spectroscopy.J. Am. Chem. Soc.1382312–2318. 10.1021/jacs.5b12680
109
PolycarpoC. R.HerringS.BerubeA.WoodJ. L.SollD.AmbrogellyA. (2006). Pyrrolysine analogues as substrates for pyrrolysyl-tRNA synthetase.FEBS Lett.5806695–6700. 10.1016/j.febslet.2006.11.028
110
RavikumarY.NadarajanS. P.YooT. H.LeeC. S.YunH. (2015). Unnatural amino acid mutagenesis-based enzyme engineering.Trends Biotechnol.33462–470. 10.1016/j.tibtech.2015.05.002
111
RogersJ. M.KwonS.DawsonS. J.MandalP. K.SugaH.HucI. (2018). Ribosomal synthesis and folding of peptide-helical aromatic foldamer hybrids.Nat. Chem.10405–412. 10.1038/s41557-018-0007-x
112
RogersonD. T.SachdevaA.WangK.HaqT.KazlauskaiteA.HancockS. M.et al (2015). Efficient genetic encoding of phosphoserine and its nonhydrolyzable analog.Nat. Chem. Biol.11496–503. 10.1038/nchembio.1823
113
RothmanD. M.PeterssonE. J.VazquezM. E.BrandtG. S.DoughertyD. A.ImperialiB. (2005). Caged phosphoproteins.J. Am. Chem. Soc.127846–847. 10.1021/ja043875c
114
SalehiA. S. M.SmithM. T.SchinnS. M.HuntJ. M.MuhlesteinC.Diray-ArceJ.et al (2017). Efficient tRNA degradation and quantification in Escherichia coli cell extract using RNase-coated magnetic beads: a key step toward codon emancipation.Biotechnol. Prog.331401–1407. 10.1002/btpr.2511
115
SandoS.OgawaA.NishiT.HayamiM.AoyamaY. (2007). In vitro selection of RNA aptamer against Escherichia coli release factor 1.Bioorg. Med. Chem. Lett.171216–1220. 10.1016/j.bmcl.2006.12.013
116
SchinnS. M.BradleyW.GroesbeckA.WuJ. C.BroadbentA.BundyB. C. (2017). Rapid in vitro screening for the location-dependent effects of unnatural amino acids on protein expression and activity.Biotechnol. Bioeng.1142412–2417. 10.1002/bit.26305
117
SekiE.YanagisawaT.YokoyamaS. (2018). Cell-free protein synthesis for multiple site-specific incorporation of noncanonical amino acids using cell extracts from rf-1 deletion E. coli Strains.Methods Mol. Biol.172849–65. 10.1007/978-1-4939-7574-7_3
118
ShaferA. M.KálaiT.LiuS. Q. B.HidegK.VossJ. C. (2004). Site-specific insertion of spin-labeled L-amino acids in Xenopus oocytes.Biochemistry438470–8482. 10.1021/bi035542i
119
ShepherdT. R.DuL.LiljeruhmJ.Samudyata, WangJ.SjödinM. O. D. (2017). De novo design and synthesis of a 30-cistron translation-factor module.Nucleic Acids Res.4510895–10905. 10.1093/nar/gkx753
120
ShimizuY.InoueA.TomariY.SuzukiT.YokogawaT.NishikawaK.et al (2001). Cell-free translation reconstituted with purified components.Nat. Biotechnol.19751–755. 10.1038/90802
121
ShortG. F.IIIGolovineS. Y.HechtS. M. (1999). Effects of release factor 1 on in vitro protein translation and the elaboration of proteins containing unnatural amino acids.Biochemistry388808–8819. 10.1021/bi990281r
122
SiL. L.XuH.ZhouX. Y.ZhangZ. W.TianZ. Y.WangY.et al (2016). Generation of influenza A viruses as live but replication-incompetent virus vaccines.Science3541170–1173. 10.1126/science.aah5869
123
SilvermanA. D.KarimA. S.JewettM. C. (2019). Cell-free gene expression: an expanded repertoire of applications.Nat. Rev. Genet.21151–170. 10.1038/s41576-019-0186-3
124
Singh-BlomA.HughesR. A.EllingtonA. D. (2014). An amino acid depleted cell-free protein synthesis system for the incorporation of non-canonical amino acid analogs into proteins.J. Biotechnol.17812–22. 10.1016/j.jbiotec.2014.02.009
125
SmolskayaS.LogashinaY. A.AndreevY. A. (2020). Escherichia coli Extract-based cell-free expression system as an alternative for difficult-to-obtain protein biosynthesis.Int. J. Mol. Sci.21:928. 10.3390/ijms21030928
126
StechM.NikolaevaO.ThoringL.StockleinW. F. M.WustenhagenD. A.HustM.et al (2017). Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates.Sci. Rep.7:12030. 10.1038/s41598-017-12364-w
127
SternerD. E.BergerS. L. (2000). Acetylation of histones and transcription-related factors.Microbiol. Mol. Biol. Rev.64435–459. 10.1128/mmbr.64.2.435-459.2000
128
SugaH. (2018). Max-Bergmann award lecture:A RaPID way to discover bioactive nonstandard peptides assisted by the flexizyme and FIT systems.J. Pept. Sci.24:e3055. 10.1002/psc.3055
129
SzkaradkiewiczK.NanningaM.Nesper-BrockM.GerritsM.ErdmannV. A.SprinzlM. (2002). RNA aptamers directed against release factor 1 from Thermus thermophilus.FEBS Lett.51490–95. 10.1016/s0014-5793(02)02308-6
130
TajimaK.KatohT.SugaH. (2018). Genetic code expansion via integration of redundant amino acid assignment by finely tuning tRNA pools.Curr. Opin. Chem. Biol.46212–218. 10.1016/j.cbpa.2018.07.010
131
ThyerR.FilipovskaA.RackhamO. (2013). Engineered rRNA enhances the efficiency of selenocysteine incorporation during translation.J. Am. Chem. Soc.1352–5. 10.1021/ja3069177
132
TomitaK.OgawaT.UozumiT.WatanabeK.MasakiH. (2000). A cytotoxic ribonuclease which specifically cleaves four isoaccepting arginine tRNAs at their anticodon loops.Proc. Natl. Acad. Sci. U.S.A.978278–8283. 10.1073/pnas.140213797
133
UrbanekA.Elena-RealC. A.PopovicM.MoratoA.FournetA.AllemandF.et al (2020). Site-specific isotopic labeling (SSIL): access to high-resolution structural and dynamic information in low-complexity proteins.Chembiochem21769–775. 10.1002/cbic.201900583
134
UrbanekA.MoratóA.AllemandF.DelaforgeE.FournetA.PopovicM.et al (2018). A general strategy to access structural information at atomic resolution in polyglutamine homorepeats.Angew. Chem.1303660–3663. 10.1002/ange.201711530
135
VenkatS.SturgesJ.StahmanA.GregoryC.GanQ.FanC. (2018). Genetically incorporating two distinct post-translational modifications into one protein simultaneously.ACS Synth. Biol.7689–695. 10.1021/acssynbio.7b00408
136
VillarrealF.Contreras-LlanoL. E.ChavezM.DingY.FanJ.PanT.et al (2018). Synthetic microbial consortia enable rapid assembly of pure translation machinery.Nat. Chem. Biol.1429–35. 10.1038/nchembio.2514
137
WakamoriM.FujiiY.SukaN.ShirouzuM.SakamotoK.UmeharaT.et al (2015). Intra- and inter-nucleosomal interactions of the histone H4 tail revealed with a human nucleosome core particle with genetically-incorporated H4 tetra-acetylation.Sci. Rep.5:17204. 10.1038/srep17204
138
WanW.HuangY.WangZ.RussellW. K.PaiP. J.RussellD. H.et al (2010). A facile system for genetic incorporation of two different noncanonical amino acids into one protein in Escherichia coli.Angew. Chem. Int. Ed. Engl.493211–3214. 10.1002/anie.201000465
139
WangH. H.HuangP. Y.XuG.HaasW.MarblestoneA.LiJ.et al (2012). Multiplexed in vivo His-tagging of enzyme pathways for in vitro single-pot multienzyme catalysis.ACS Synth. Biol.143–52. 10.1021/sb3000029
140
WangK.NeumannH.Peak-ChewS. Y.ChinJ. W. (2007). Evolved orthogonal ribosomes enhance the efficiency of synthetic genetic code expansion.Nat. Biotechnol.25770–777. 10.1038/nbt1314
141
WangK.SachdevaA.CoxD. J.WilfN. M.LangK.WallaceS.et al (2014). Optimized orthogonal translation of unnatural amino acids enables spontaneous protein double-labelling and FRET.Nat. Chem.6393–403. 10.1038/nchem.1919
142
WangL. (2017). Engineering the genetic code in cells and animals: biological considerations and impacts.Acc. Chem. Res.502767–2775. 10.1021/acs.accounts.7b00376
143
WangT.LiangC.AnY.XiaoS.XuH.ZhengM.et al (2020). Engineering the translational machinery for biotechnology applications.Mol. Biotechnol.62219–227. 10.1007/s12033-020-00246-y
144
WangY. S.FangX.WallaceA. L.WuB.LiuW. R. (2012). A rationally designed pyrrolysyl-tRNA synthetase mutant with a broad substrate spectrum.J. Am. Chem. Soc.1342950–2953. 10.1021/ja211972x
145
WannierT. M.KunjapurA. M.RiceD. P.McDonaldM. J.DesaiM. M.ChurchG. M. (2018). Adaptive evolution of genomically recoded Escherichia coli.Proc. Natl. Acad. Sci. U.S.A.1153090–3095. 10.1073/pnas.1715530115
146
WorstE. G.ExnerM. P.De SimoneA.SchenkelbergerM.NoireauxV.BudisaN.et al (2015). Cell-free expression with the toxic amino acid canavanine.Bioorg. Med. Chem. Lett.253658–3660. 10.1016/j.bmcl.2015.06.045
147
WorstE. G.ExnerM. P.De SimoneA.SchenkelbergerM.NoireauxV.BudisaN.et al (2016). Residue-specific incorporation of noncanonical amino acids into model proteins using an Escherichia coli Cell-free Transcription-translation System.J. Vis. Exp.1:54273. 10.3791/54273
148
XiaoH.MurakamiH.SugaH.Ferre-D’AmareA. R. (2008). Structural basis of specific tRNA aminoacylation by a small in vitro selected ribozyme.Nature454358–361. 10.1038/nature07033
149
XiaoH.PetersF. B.YangP. Y.ReedS.ChittuluruJ. R.SchultzP. G. (2014). Genetic incorporation of histidine derivatives using an engineered pyrrolysyl-tRNA synthetase.ACS Chem. Biol.91092–1096. 10.1021/cb500032c
150
XiongH.ReynoldsN. M.FanC.EnglertM.HoyerD.MillerS. J.et al (2016). Dual genetic encoding of acetyl-lysine and non-deacetylatable thioacetyl-lysine mediated by flexizyme.Angew. Chem. Int. Ed. Engl.554083–4086. 10.1002/anie.201511750
151
YamanakaK.NakataH.HohsakaT.SisidoM. (2004). Efficient synthesis of nonnatural mutants in Escherichia coli S30 in vitro protein synthesizing system.J. Biosci. Bioeng.97395–399. 10.1016/s1389-1723(04)70225-x
152
YanagisawaT.TakahashiM.MukaiT.SatoS.WakamoriM.ShirouzuM.et al (2014). Multiple site-specific installations ofNε-Monomethyl-L-Lysine into histone proteins by cell-based and cell-free protein synthesis.ChemBioChem151830–1838. 10.1002/cbic.201402291
153
YinG.StephensonH. T.YangJ.LiX.ArmstrongS. M.HeibeckT. H.et al (2017). RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.Sci. Rep.7:3026. 10.1038/s41598-017-03192-z
154
ZhangM. S.BrunnerS. F.Huguenin-DezotN.LiangA. D.SchmiedW. H.RogersonD. T.et al (2017). Biosynthesis and genetic encoding of phosphothreonine through parallel selection and deep sequencing.Nat. Methods14729–736. 10.1038/nmeth.4302
155
ZhengY.GilgenastM. J.HaucS.ChatterjeeA. (2018). capturing post-translational modification-triggered protein-protein interactions using dual noncanonical amino acid mutagenesis.ACS Chem. Biol.131137–1141. 10.1021/acschembio.8b00021
156
ZhuP.GafkenP. R.MehlR. A.CooleyR. B. (2019). A highly versatile expression system for the production of multiply phosphorylated proteins.ACS Chem. Biol.141564–1572. 10.1021/acschembio.9b00307
157
ZimmermanE. S.HeibeckT. H.GillA.LiX.MurrayC. J.MadlansacayM. R. (2014). Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.Bioconjug Chem.25351–361. 10.1021/bc400490z
Summary
Keywords
cell-free synthetic biology, cell-free protein synthesis, non-canonical amino acids, competition elimination, in vitro aminoacylation
Citation
Wu Y, Wang Z, Qiao X, Li J, Shu X and Qi H (2020) Emerging Methods for Efficient and Extensive Incorporation of Non-canonical Amino Acids Using Cell-Free Systems. Front. Bioeng. Biotechnol. 8:863. doi: 10.3389/fbioe.2020.00863
Received
27 April 2020
Accepted
06 July 2020
Published
22 July 2020
Volume
8 - 2020
Edited by
Yuan Lu, Tsinghua University, China
Reviewed by
Seok Hoon Hong, Illinois Institute of Technology, United States; Dong-Myung Kim, Chungnam National University, South Korea
Updates
Copyright
© 2020 Wu, Wang, Qiao, Li, Shu and Qi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Qi, haoq@tju.edu.cn
This article was submitted to Synthetic Biology, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.